Advertisement
BDX or CNMD or TMO
Which Stock Would AI Choose? Becton, Dickinson and Company (BDX) vs. CONMED Corporation (CNMD) vs. Thermo Fisher Scientific Inc. (TMO) Stock Comparison
Key Takeaways
- TMO leads with year-to-date (YTD) gains of nearly 19%, far outpacing BDX at 1.5% and CNMD's prolonged underperformance.
- All three stocks trade at similar price-to-earnings (P/E) ratios around 24-26, reflecting balanced valuations in the medtech sector.
- Recent quarterly earnings beats for BDX, CNMD, and TMO, though CNMD shows year-over-year sales declines.
- TMO's strategic expansions and divestitures provide fresh growth catalysts, while BDX benefits from product innovations.
- CNMD, as the smallest by market cap, carries higher volatility amid recent market weakness.
- Healthcare sector tailwinds support relative stability across these medtech peers amid broader market fluctuations.
Introduction
This comparison examines BDX, CNMD, and TMO, three prominent players in the medical technology and life sciences sectors. These stocks appeal to investors seeking exposure to healthcare innovation, including devices, diagnostics, and biopharma tools. Traders focused on relative performance may find value in their contrasting momentum, valuations, and catalysts during recent market activity. With medtech demand driven by aging populations and procedural growth, understanding their positioning aids portfolio diversification and trend analysis.
BDX Overview and Recent Performance
BDX, or Becton, Dickinson and Company, is a global leader in medical supplies, devices, and diagnostics, spanning infusion therapy, vascular access, and laboratory solutions. Its market cap stands at approximately $42 billion, with a P/E ratio of 24.4. In recent weeks, shares have traded near $149, within a 52-week range of $128 to $187. Q1 2026 results exceeded expectations with revenues of $5.3 billion, supporting sentiment despite anticipated Q2 declines. Key influences include FDA clearance for the Surgiphor irrigation system and employee well-being recognitions, offsetting share weakness tied to broader sector pressures and analyst target adjustments.
CNMD Overview and Recent Performance
CNMD, CONMED Corporation, specializes in surgical devices and equipment for orthopedic, general surgery, and laparoscopy procedures. With a smaller market cap around $1 billion, it maintains a P/E ratio near 21. Shares have faced prolonged weakness, trading in the mid-$30s amid a challenging 52-week range. Recent Q1 2026 earnings beat estimates with adjusted EPS of $0.89 and revenues of $317 million, though sales dipped 1.3% year-over-year. Sentiment reflects high-margin segment growth but is tempered by overall share declines over the past year, influenced by market dynamics and competitive pressures in surgical markets.
TMO Overview and Recent Performance
TMO, Thermo Fisher Scientific Inc., dominates life sciences solutions, analytical instruments, and biopharma services across four segments. Boasting a $174 billion market cap and P/E of 25.8, shares hover around $469 in a 52-week range of $385 to $644. Recent market activity shows YTD strength at 19%, bolstered by the $1 billion sale of its microbiology business to Astorg and the opening of a U.S. bioprocess design center. Q1 results and expansions in cell/gene therapy manufacturing have driven positive momentum, despite some post-earnings dips, amid robust analyst support.
Trending AI Robots
Tickeron's Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available on the platform, which collectively trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like trend-following, technical/fundamental analysis, and multi-agent systems, with timeframes from 5 minutes to 60 minutes. Standout stats include annualized returns up to 163%, win rates as high as 88%, profit factors over 7, and profit-to-drawdown ratios exceeding 17—often outperforming the S&P 500 in recent months. Focused on high-volatility sectors like semiconductors and industrials, they offer customizable risk management. Explore these bots to align with current market conditions and enhance trading efficiency.
Head-to-Head Comparison
BDX, CNMD, and TMO operate in medtech but diverge in focus: BDX emphasizes infusion and vascular devices, CNMD surgical instrumentation, and TMO broader life sciences/biopharma tools. Growth drivers include TMO's bioprocessing expansions versus CNMD's procedure volumes. Recent momentum favors TMO, with superior YTD returns, while BDX shows stability and CNMD lags due to sales softness. Risks are elevated for small-cap CNMD; all share sector exposure to regulatory shifts. Valuations align closely, but TMO commands a premium for scale. Sentiment tilts toward TMO's catalysts amid healthcare tailwinds.
Tickeron AI Verdict
Tickeron's AI models would likely favor TMO in the current environment, given its trend consistency, YTD outperformance, and catalysts like bioprocess investments and strategic divestitures. BDX offers reliable stability for conservative positioning, while CNMD presents higher-risk rebound potential. Relative strength points to TMO for probabilistic edge in medtech trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 1 FA rating(s) are green whileCNMD’s FA Score has 2 green FA rating(s), and TMO’s FA Score reflects 0 green FA rating(s).
- BDX’s FA Score: 1 green, 4 red.
- CNMD’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 4 TA indicator(s) are bullish while CNMD’s TA Score has 4 bullish TA indicator(s), and TMO’s TA Score reflects 4 bullish TA indicator(s).
- BDX’s TA Score: 4 bullish, 4 bearish.
- CNMD’s TA Score: 4 bullish, 4 bearish.
- TMO’s TA Score: 4 bullish, 6 bearish.
Price Growth
BDX (@Pharmaceuticals: Other) experienced а -3.99% price change this week, while CNMD (@Medical/Nursing Services) price change was -3.45% , and TMO (@Medical Specialties) price fluctuated -5.73% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -4.52%. For the same industry, the average monthly price growth was -4.78%, and the average quarterly price growth was +19.71%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.53%. For the same industry, the average monthly price growth was -5.85%, and the average quarterly price growth was -5.88%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +10.58%. For the same industry, the average monthly price growth was +4.66%, and the average quarterly price growth was -5.70%.
Reported Earning Dates
BDX is expected to report earnings on Jul 30, 2026.
CNMD is expected to report earnings on Jul 29, 2026.
TMO is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-4.52% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-1.53% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+10.58% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BDX | CNMD | TMO | |
| Capitalization | 39.5B | 1.07B | 163B |
| EBITDA | 4.97B | 187M | 11.7B |
| Gain YTD | -5.393 | -12.586 | -24.278 |
| P/E Ratio | 25.04 | 20.05 | 24.10 |
| Revenue | 22.2B | 1.37B | 45.2B |
| Total Cash | 816M | 35M | 3.26B |
| Total Debt | 17.3B | 861M | 43.2B |
BDX | CNMD | TMO | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 11 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 17 Undervalued | 39 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 86 | 84 | 60 | |
PRICE GROWTH RATING 1..100 | 61 | 83 | 64 | |
P/E GROWTH RATING 1..100 | 76 | 24 | 46 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDX's Valuation (15) in the Medical Specialties industry is in the same range as CNMD (17) and is in the same range as TMO (39). This means that BDX's stock grew similarly to CNMD’s and similarly to TMO’s over the last 12 months.
BDX's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as CNMD (100) and is in the same range as TMO (100). This means that BDX's stock grew similarly to CNMD’s and similarly to TMO’s over the last 12 months.
TMO's SMR Rating (60) in the Medical Specialties industry is in the same range as CNMD (84) and is in the same range as BDX (86). This means that TMO's stock grew similarly to CNMD’s and similarly to BDX’s over the last 12 months.
BDX's Price Growth Rating (61) in the Medical Specialties industry is in the same range as TMO (64) and is in the same range as CNMD (83). This means that BDX's stock grew similarly to TMO’s and similarly to CNMD’s over the last 12 months.
CNMD's P/E Growth Rating (24) in the Medical Specialties industry is in the same range as TMO (46) and is somewhat better than the same rating for BDX (76). This means that CNMD's stock grew similarly to TMO’s and somewhat faster than BDX’s over the last 12 months.
| BDX | CNMD | TMO | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 48% | N/A | 3 days ago 45% |
| Stochastic ODDS (%) | 3 days ago 55% | 3 days ago 72% | 3 days ago 60% |
| Momentum ODDS (%) | 3 days ago 47% | 3 days ago 77% | 3 days ago 56% |
| MACD ODDS (%) | 3 days ago 48% | 3 days ago 74% | 3 days ago 64% |
| TrendWeek ODDS (%) | 3 days ago 43% | 3 days ago 79% | 3 days ago 60% |
| TrendMonth ODDS (%) | 3 days ago 43% | 3 days ago 76% | 3 days ago 66% |
| Advances ODDS (%) | 11 days ago 43% | 11 days ago 68% | 11 days ago 63% |
| Declines ODDS (%) | 7 days ago 41% | 7 days ago 80% | 7 days ago 63% |
| BollingerBands ODDS (%) | 3 days ago 52% | 3 days ago 79% | 3 days ago 53% |
| Aroon ODDS (%) | 3 days ago 42% | 3 days ago 60% | 3 days ago 56% |
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with TMO. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | -0.69% | ||
| TMO - BDX | 50% Loosely correlated | -2.20% | ||
| COO - BDX | 48% Loosely correlated | -1.28% | ||
| CNMD - BDX | 48% Loosely correlated | -2.34% | ||
| BAX - BDX | 47% Loosely correlated | -2.70% | ||
| RVTY - BDX | 45% Loosely correlated | -2.50% | ||
More | ||||
CNMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, CNMD has been loosely correlated with ENOV. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if CNMD jumps, then ENOV could also see price increases.
| Ticker / NAME | Correlation To CNMD | 1D Price Change % | ||
|---|---|---|---|---|
| CNMD | 100% | -2.34% | ||
| ENOV - CNMD | 59% Loosely correlated | -7.01% | ||
| IART - CNMD | 57% Loosely correlated | -2.76% | ||
| KIDS - CNMD | 53% Loosely correlated | -1.01% | ||
| NVST - CNMD | 49% Loosely correlated | -2.68% | ||
| VREX - CNMD | 48% Loosely correlated | -3.59% | ||
More | ||||
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with MTD. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then MTD could also see price increases.